Enhancing mTOR-targeted cancer therapy

Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy

(2010) Xuerong Wang et al.   CANCER BIOLOGY & THERAPY

Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001

(2009) Philipp Baumann et al.   ANTI-CANCER DRUGS

A complex interplay between Akt, TSC2 and the two mTOR complexes: Figure 1

(2009) Jingxiang Huang et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

(2009) Eva Juengel et al.   BMC CANCER

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

(2009) Robert J. Amato et al.   CANCER

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2

(2009) J. Copp et al.   CANCER RESEARCH

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

(2009) K. Yu et al.   CANCER RESEARCH

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

New Insights into mTOR Signaling: mTORC2 and Beyond

(2009) D. R. Alessi et al.   Science Signaling

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

(2009) Nancy Lee et al.   BMC Pharmacology & Toxicology

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

(2008) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs

(2008) R Bianco et al.   BRITISH JOURNAL OF CANCER

Role of LKB1 in lung cancer development

(2008) L Makowski et al.   BRITISH JOURNAL OF CANCER

Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation

(2008) X. Wang et al.   CANCER RESEARCH

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy

(2008) J. R. Graff et al.   CANCER RESEARCH

PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel

(2008) L. Yang et al.   CLINICAL CANCER RESEARCH

Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation

(2008) Audrey Carrière et al.   CURRENT BIOLOGY

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations

(2008) J LOPICCOLO et al.   DRUG RESISTANCE UPDATES

Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

(2008) Tsuneo Ikenoue et al.   EMBO JOURNAL

The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C

(2008) Valeria Facchinetti et al.   EMBO JOURNAL

Wnt Signaling Inhibits Forkhead Box O3a-induced Transcription and Apoptosis through Up-regulation of Serum- and Glucocorticoid-inducible Kinase 1

(2008) Manuel Dehner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulation of Proline-rich Akt Substrate of 40 kDa (PRAS40) Function by Mammalian Target of Rapamycin Complex 1 (mTORC1)-mediated Phosphorylation

(2008) Lifu Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

(2008) Viraj J. Jasinghe et al.   JOURNAL OF HEPATOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Regulation of mTORC1 and mTORC2 Complex Assembly by Phosphatidic Acid: Competition with Rapamycin

(2008) A. Toschi et al.   MOLECULAR AND CELLULAR BIOLOGY

The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2

(2008) J. Huang et al.   MOLECULAR AND CELLULAR BIOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Phospholipase D1 is an effector of Rheb in the mTOR pathway

(2008) Y. Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression

(2008) Jian-Hua Mao et al.   SCIENCE

Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells

(2007) Amalia Azzariti et al.   BIOCHEMICAL PHARMACOLOGY

Eukaryotic initiation factor 4E

(2007) Ian G. Goodfellow et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY